VOCs in Patients With Acute Cardiogenic Chest Pain

NCT ID: NCT06277895

Last Updated: 2024-02-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

1400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-26

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observation study is to compare VOCs in cardiogenic chest pain population/health conditions, to answer:Establishment and promotion of the application system of emergency rapid detection of expiratory Volatile Organic Compounds (VOCs) in patients with acute cardiogenic chest pain

1. VOCs levels were measured at baseline in healthy people, and markers of VOCs that could be used to identify acute cardiogenic chest pain were sought.
2. The relationship between abnormal VOCs (mainly aldehydes) and prognosis of patients and the correlation with Super-score for early warning of acute heart failure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome Acute Aortic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cardiogenic chest pain group

cardiogenic chest pain group/acute coronary syndrome

Group Type EXPERIMENTAL

VOCs

Intervention Type DIAGNOSTIC_TEST

test the end-expiratory gas

normal group

Healthy population

Group Type OTHER

VOCs

Intervention Type DIAGNOSTIC_TEST

test the end-expiratory gas

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VOCs

test the end-expiratory gas

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Over 18 years old, male or female;
2. Patients with acute cardiogenic chest pain (see diagnostic criteria);
3. Patient\'s informed consent.


1. Over 18 years old, male or female;
2. Centerless cerebrovascular disease, lung disease, no abnormal liver and kidney function, no acute infection recently;
3. Informed consent.

Exclusion Criteria

1. The patient had difficulty in collecting breath;
2. Patients with terminal illness or receiving palliative care;
3. Have participated in other clinical studies or consider it inappropriate to participate in this study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Qilu Hospital of Shandong University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Qilu hospital

Jinan, Shandong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yuan Bian, Dr.

Role: CONTACT

+8618560083065

Xiuting Yang, Dr.

Role: CONTACT

800-872-5327

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

yuan bian

Role: primary

18560084775

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KYLL-202401-047

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.